Current and future directions for treating hepatitis B virus infection

Table 5 Treatment efficacy of tenofovir in chronic hepatitis B

Ref.	No. of patients	HBeAg	Therapy regimen	HBeAg loss (%)/seroconversion from HBeAg to anti-HBe (%)	Undetectable of HBV DNA (%)	Normalization of ALT (%)	HBsAg loss (n)
1Marcellin et al[83]	176 NUCs - treatment-naive	Positive	TDF 300 mg daily (> 48 wk)	NA/21	76	68	5
	90	Positive	ADF 10 mg daily (> 48 wk)	NA/18	13	54	0
	90	Positive	ADF (48 wk)	NA/18	13	54	0
	125	Negative	ADF (48 wk)	NA/NA	63	77	0
2Heathcote et al[88]	266	Positive	TDF (> 144 wk)	34/26	71	74	20
	365	Negative	TDF (> 144 wk)	NA/NA	87	81	0
2Marcellin et al[91]	266	Positive	TDF (> 240 wk)	49/40	65	73	10
	375	Negative	TDF (> 240 wk)	NA/NA	83	85	1

The treatment efficacies were assessed at 48 wk¹, or 144 wk². TDF: Tenofovir; ADF: Adefovir; NA: Not available; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBsAg: Hepatitis B s antigen; Anti-HBe: Antibody to HBe antigen.